SCHEMBL29708173

SCHEMBL29708173

NC(=O)C[C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 3/20 0.46
▸ ECE1 P42892 1/20 0.39
▸ KISS1R Q969F8 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31050430 0.93 MME (0.51) MME
SCHEMBL29851664 0.91 MME (0.38) MMEECE1
SCHEMBL30788355 0.89 MME (0.43) MME
SCHEMBL30788364 0.89 MME (0.51) MME
SCHEMBL30819418 0.87 UTS2R (0.43) MMEECE1
SCHEMBL30209180 0.86 PDCD1LG2 (0.36) MMEECE1
SCHEMBL29913867 0.86 ECE1 (0.36) MMEECE1KISS1R
SCHEMBL29546019 0.85 MME (0.51) MMEECE1
SCHEMBL29378004 0.85 MME (0.37) MMEECE1
SCHEMBL5318831 0.84 UTS2R (0.32) MMEECE1KISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025227105-A1 CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2025-10-30 — — WO disclosed
US-20240269293-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF OD THERAPEUTICS LIMITED (CN) 2024-08-15 — — US disclosed
EP-4313154-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF OD Therapeutics Limited (HK) 2024-02-07 — — EP disclosed
US-20220401561-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF AJ SCIENCES (YIXING) CO., LTD (CN) 2022-12-22 — — US disclosed
WO-2022212362-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) 2022-10-06 — — WO disclosed
EP-4037715-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF Beijing Xuanyi Pharmasciences Co., Ltd. (CN) 2022-08-10 — — EP disclosed
CN-114630818-A Protein-macromolecule conjugates and methods of use thereof 北京轩义医药科技有限公司 2022-06-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269293-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF CD44, MACROD1, MSN MME 714/4885ECE1 2781/4885KISS1R 4348/4885
US-20220401561-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF CD44, SSB, DNPEP MME 442/4885ECE1 2076/4885KISS1R 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback